


What is claimed is:

1. A compound of Formula I:



wherein

R¹ is a 5 or 6 membered aryl, heteroaryl or heterocyclic group wherein each heteroaryl or heterocyclic group contains from 1 to 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur; and wherein the aryl, heteroaryl or heterocyclic group is optionally substituted with 1 or 2 groups independently selected from the group consisting of -C₁-C₆ alkyl, -C₃-C₆ cycloalkyl, C₁-C₆ alkylC₃-C₆ cycloalkyl, halogen, -C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, and -C(O)C₁-C₆ alkyl;

R² and R^{2'} are at each occurrence independently H or -C₁-C₆ alkyl; or one set of R² and R^{2'} combine with the carbon atom to which they are both attached to form a C₃-C₆ cycloalkyl group;

R³ is H, -C₁-C₆ alkyl or C₃-C₆ cycloalkyl,

R⁴ is H, -C₁-C₆ alkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, -C₃-C₆ cycloalkyl, or halo;

R⁵ is a 5 or 6 membered aryl, heteroaryl or heterocyclic group optionally substituted with one, two or three groups independently selected from the group consisting of -C₁-C₆ alkyl, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₁-C₆ alkylC₃-C₆ cycloalkyl, -C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, -O-aryl, and halo; wherein the cycloalkyl group is optionally substituted with -C₁-C₆ alkyl or -C₁-C₆ haloalkyl; and

wherein the substituent -O-aryl group is optionally substituted with -C₁-C₆ alkyl, halo, C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, or -OC₁-C₆ haloalkyl; and wherein two substituents on the aryl, heteroaryl, or heterocyclic ring of R⁵ optionally combine to form a 8-12 membered bicyclic ring optionally containing one or two oxygen atoms; and wherein the bicyclic ring is optionally substituted with 1 or 2 groups independently selected from the group consisting of -C₁-C₆ alkyl, -C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, -C₃-C₆ cycloalkyl, and halo;

R⁶ is H, -C₁-C₆ alkyl, -C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, or halo; or R⁶ combines with the aryl, heteroaryl or heterocyclic ring of R⁵ to form a tetracyclic ring

optionally substituted with 1 or 2 groups independently selected from C₁-C₆ alkyl, -C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, -C₃-C₆ cycloalkyl, and halo;

R⁷ is H, -C₁-C₆ alkyl, -C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, -C₁-C₆ haloalkyl, or halo;

n = 1 – 4;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 wherein,

R¹ is a pyrimidinyl, pyridinyl, imidazolyl, thiazolyl, oxazolyl, or triazolyl group optionally substituted with 1 or 2 groups independently selected from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, halogen, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, -OC₁-C₆ haloalkyl, and -C(O)C₁-C₆ alkyl;

R² and R^{2'} are at each occurrence independently H or C₁-C₆ alkyl; or one set of R² and R^{2'} combines with the carbon atom to which they are both attached to form a cycloalkyl group having from 3 to 6 carbon atoms;

R³ is H or -C₁-C₆ alkyl;

R⁴ is H, -C₁-C₆ alkyl, or halo;

R⁵ is a phenyl group substituted with one or two groups independently selected from the group consisting of -C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -C₁-C₆ alkylC₃-C₆ cycloalkyl, -C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, -O-aryl, and halo; wherein the cycloalkyl group is optionally substituted with C₁-C₆ alkyl or C₁-C₆ haloalkyl; wherein the substituent -O-aryl group is optionally substituted with C₁-C₆ alkyl, halo, C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, or -OC₁-C₆ haloalkyl; wherein two substituents on the phenyl ring of R⁵ optionally combine to form a bicyclic ring optionally containing one or two oxygen atoms; and wherein the bicyclic ring is optionally substituted with 1 or 2 groups independently selected from the group consisting of -C₁-C₆ alkyl and halogen;

R⁶ is H, -C₁-C₆ alkyl, -C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, or halo; or R⁶ combines with the phenyl ring of R⁵ to form a tetracyclic ring optionally substituted with 1 or 2 groups independently selected from C₁-C₆ alkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, -C₃-C₆ cycloalkyl, and halo;

R⁷ is H, -C₁-C₆ alkyl, -C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, -C₁-C₆ haloalkyl, or halo;

n = 1 – 4;

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 wherein:

R¹ is a pyrimidinyl, pyridinyl, imidazolyl, thiazolyl, oxazolyl, or triazolyl group optionally substituted with 1 or 2 groups independently selected from the group consisting of C₁-C₃ alkyl, and C₃-C₆ cycloalkyl;

R² and R^{2'} are at each occurrence independently H or C₁-C₃ alkyl; or one set of R² and R^{2'} optionally combine with the carbon atom to which they are both attached to form a cycloalkyl group having from 3 to 6 carbon atoms;

R³ is H or -C₁-C₆ alkyl;

R⁴ is H, or -C₁-C₆ alkyl;

R⁵ is a phenyl group substituted with one or two groups independently selected from the group consisting of -C₁-C₃ alkyl, C₃-C₆ cycloalkyl, -C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -C₁-C₃ haloalkyl, -OC₁-C₃ alkyl, -OC₁-C₃ haloalkyl, -O-aryl, and halo;

R⁶ is H, -C₁-C₃ alkyl, -C₁-C₃ haloalkyl, -OC₁-C₆ alkyl, -OC₁-C₃ haloalkyl, or halo; or R⁶ combines with the phenyl ring of R⁵ to form a tetracyclic ring optionally substituted with 1 or 2 groups independently selected from C₁-C₆ alkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, -C₃-C₆ cycloalkyl, and halo;

R⁷ is H, -C₁-C₃ alkyl, -C₁-C₃ haloalkyl, -OC₁-C₃ alkyl, -C₁-C₃ haloalkyl, or halo;

n = 1 – 2;

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 wherein,

R¹ is a pyrimidinyl, pyridinyl, imidazolyl, or thiazolyl group optionally substituted with 1 or 2 groups independently selected from the group consisting of C₁-C₃ alkyl, C₃-C₆ cycloalkyl and halo;

R² and R^{2'} are at each occurrence independently H or C₁-C₃ alkyl; or one set of R² and R^{2'} optionally combine with the carbon atom to which they are both attached to form a cyclopropyl group;

R³ is H or -C₁-C₆ alkyl;

R⁴ is H;

R⁵ is a phenyl group substituted with one or two groups independently selected from the group consisting of -C₁-C₃ alkyl, -C₁-C₃ haloalkyl, -OC₁-C₃ alkyl, -OC₁-C₃ haloalkyl, and halo;

R⁶ is H, or -C₁-C₃ alkyl;

R⁷ is H, or -C₁-C₃ alkyl;

n = 1 – 2;

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 wherein R¹ is pyridinyl or pyrimidinyl.
6. The compound according to claim 1 wherein R¹ is thiazolyl or imidazolyl.
7. The compound according to claim 1 wherein R¹ is pyridinyl or thiazolyl.
8. The compound of according to claim 1 wherein:
R¹ is a pyridine, pyrimidine, imidazolyl, or thiazolyl group each optionally substituted with 1 or 2 groups independently selected from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, halogen, C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, and -C(O)C₁-C₆ alkyl;
R² and R^{2'} are at each occurrence independently H or C₁-C₆ alkyl; or one set of R² and R^{2'} combine with the carbon atom to which they are both attached to form a C₃-C₆ cycloalkyl group;
R³ is H or -C₁-C₆ alkyl;
R⁴ is H, or -C₁-C₆ alkyl;
R⁵ is phenyl optionally substituted with one, two or three groups independently selected from the group consisting of -C₁-C₆ alkyl, -C₀-C₆ alkyl, C₃-C₆ cycloalkyl, -C₁-C₆ haloalkyl, -OC₁-C₆ alkyl, -OC₁-C₆ haloalkyl, -O-aryl, and halo; wherein the cycloalkyl group is optionally substituted with -C₁-C₆ alkyl or -C₁-C₆ haloalkyl; and
n is 1 or 2; or a pharmaceutically acceptable salt thereof.
9. The compound of according to claim 1 or 2 wherein
R³ and R⁴ independently hydrogen or methyl.
10. A compound selected from the group consisting of:
6-[3-fluoro-4-(trifluoromethoxy)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
6-[2-methoxy-4-(trifluoromethoxy)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
6-[2-methyl-4-(trifluoromethoxy)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
6-[2-fluoro-4-(trifluoromethoxy)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
8-fluoro-3-(pyrimidin-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
8-fluoro-6-[3-methyl-4-(trifluoromethoxy)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
6-(3-chloro-4-fluorophenyl)-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
6-(4-chloro-3-fluorophenyl)-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-[3-methyl-4-(trifluoromethoxy)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
 3-[(3-fluoropyridin-2-yl)methyl]-4-methyl-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 4-methyl-6-(3-phenoxyphenyl)-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
 6-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
 6-[3-(difluoromethoxy)phenyl]-4-methyl-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
 4-methyl-3-(pyrimidin-2-ylmethyl)-6-[3-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 1-[4-[4-methyl-2-oxo-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-6-yl]phenyl]cyclopropane-1-carbonitrile;
 4-methyl-3-(pyrimidin-2-ylmethyl)-6-[4-(trifluoromethyl)phenyl]-4H-1,3-benzoxazin-2-one;
 4-methyl-3-(pyrimidin-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 3-(pyrimidin-2-ylmethyl)-6-[4-(trifluoromethyl)phenyl]-4H-1,3-benzoxazin-2-one;
 3-(pyrimidin-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 3-(pyridin-4-ylmethyl)-6-[4-(trifluoromethyl)phenyl]-4H-1,3-benzoxazin-2-one; or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 1 wherein

R^6 and R^7 are independently selected from the group consisting of hydrogen, methyl, and fluoro.

12. The compound according to claim 1 wherein:

R^1 is a 5-membered heterocyclic group;

one set of R^2 and $R^{2'}$ combine to form a cyclopropyl group;

R^3 and R^4 are each H;

R^5 is a phenyl group optionally substituted with one or two groups independently selected from C_1 - C_3 alkyl, $-C_1$ - C_3 haloalkyl, $-OC_1$ - C_3 alkyl, $-OC_1$ - C_3 haloalkyl, and halo;

R^6 and R^7 are both H; and

n is 3; or a pharmaceutically acceptable salt thereof.

13. A compound according to claim 1 wherein R^1 is selected from the group consisting of: imidazolyl and thiazolyl, optionally substituted with a C_1 - C_6 alkyl group.

14. The compound according to claim 13 wherein the optional C_1 - C_6 alkyl group substituent is methyl.

15. A compound selected from the group consisting of:
 3-[[1-[(2-methylimidazol-1-yl)methyl]cyclopropyl]methyl]-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 3-[[1-[(2-methylimidazol-1-yl)methyl]cyclopropyl]methyl]-6-[4-(trifluoromethyl)phenyl]-4H-1,3-benzoxazin-2-one;
 6-[2-fluoro-4-(trifluoromethoxy)phenyl]-3-[[1-[(2-methylimidazol-1-yl)methyl]cyclopropyl]methyl]-4H-1,3-benzoxazin-2-one;
 3-[[1-[(2-methylimidazol-1-yl)methyl]cyclopropyl]methyl]-6-[3-methyl-4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 6-[2-methoxy-4-(trifluoromethoxy)phenyl]-3-[[1-[(2-methylimidazol-1-yl)methyl]cyclopropyl]methyl]-4H-1,3-benzoxazin-2-one; or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 1 wherein:
 R^1 is a 5-membered heterocyclic group;
 one set of R^2 and $R^{2'}$ combine to form a cyclopropyl group;
 R^3 and R^4 are each H;
 R^5 is a phenyl group optionally substituted with one or two groups independently selected from C_1 - C_3 alkyl, $-C_1$ - C_3 haloalkyl, $-OC_1$ - C_3 alkyl, $-OC_1$ - C_3 haloalkyl, and halo;
 R^6 and R^7 are both H; and
 n is 1; or a pharmaceutically acceptable salt thereof.

17. The compound according to claim 15 selected from the group consisting of:
 6-[2-methoxy-4-(trifluoromethoxy)phenyl]-3-(1-pyridin-2-ylcyclopropyl)-4H-1,3-benzoxazin-2-one;
 6-[3-methyl-4-(trifluoromethoxy)phenyl]-3-(1-pyridin-2-ylcyclopropyl)-4H-1,3-benzoxazin-2-one;
 6-[2-fluoro-4-(trifluoromethoxy)phenyl]-3-(1-pyridin-2-ylcyclopropyl)-4H-1,3-benzoxazin-2-one;
 3-(1-pyridin-2-ylcyclopropyl)-6-[4-(trifluoromethyl)phenyl]-4H-1,3-benzoxazin-2-one;
 3-(1-pyridin-2-ylcyclopropyl)-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 1 wherein:

R¹ is a 6-membered heterocyclic

R² and R^{2'} are both H;

R³ is H or C₁-C₆ alkyl;

R⁴ is H or C₁-C₆ alkyl;

R⁵ is a phenyl group optionally substituted with one or two groups independently selected from C₁-C₃ alkyl, -C₁-C₃ haloalkyl, -OC₁-C₃ alkyl, -OC₁-C₃ haloalkyl, and halo

R⁶ and R⁷ are both H; and

n is 1; or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 17 wherein:

R¹ is a pyrimidinyl optionally substituted with C₁-C₆ alkyl;

R^{2a} and R^{2b} are both H;

R³ is CH₃;

R⁴ is H;

R⁵ is a phenyl group optionally substituted with one or two groups independently selected from -OCF₃, halogen, CH₃, or -OCH₃;

R⁶ and R⁷ are both H; and

n is 1; or a pharmaceutically acceptable salt thereof.

20. The compound according to claim 18 selected from the group consisting of:

6-[2-fluoro-4-(trifluoromethoxy)phenyl]-4-methyl-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

4-methyl-6-[2-methyl-4-(trifluoromethoxy)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

4-methyl-6-[3-methyl-4-(trifluoromethoxy)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-(4-chloro-3-fluorophenyl)-4-methyl-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-(3,4-dichlorophenyl)-4-methyl-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-[2-methoxy-4-(trifluoromethoxy)phenyl]-4-methyl-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-[3-(difluoromethoxy)phenyl]-4-methyl-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
 4-methyl-3-(pyrimidin-2-ylmethyl)-6-[3-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 1-[4-[4-methyl-2-oxo-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-6-yl]phenyl]cyclopropane-
 1-carbonitrile;
 4-methyl-3-(pyrimidin-2-ylmethyl)-6-[4-(trifluoromethyl)phenyl]-4H-1,3-benzoxazin-2-one;
 4-methyl-3-(pyrimidin-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 1 wherein

R¹ is a pyrimidinyl optionally substituted with C₁-C₆ alkyl;

R^{2a} and R^{2b} are both H;

R³ is H;

R⁴ is H;

R⁵ is a phenyl group optionally substituted with one or two groups independently selected from -OCF₃, halogen, CH₃, or -OCH₃;

R⁶ and R⁷ are both H; and

n is 1; or a pharmaceutically acceptable salt thereof.

22. A compound according to claim 20 selected from the group consisting of:

3-[(5-methylpyrimidin-2-yl)methyl]-6-[2-methyl-4-(trifluoromethyl)phenyl]-4H-1,3-benzoxazin-2-one;

6-[2-methoxy-4-(trifluoromethyl)phenyl]-3-[(5-methylpyrimidin-2-yl)methyl]-4H-1,3-benzoxazin-2-one;

6-[2-fluoro-4-(trifluoromethyl)phenyl]-3-[(5-methylpyrimidin-2-yl)methyl]-4H-1,3-benzoxazin-2-one;

6-[2-ethoxy-4-(trifluoromethoxy)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-[2-propan-2-yloxy-4-(trifluoromethoxy)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

3-(pyrimidin-2-ylmethyl)-6-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]-4H-1,3-benzoxazin-2-one;

6-[2-methyl-4-(trifluoromethyl)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-[2-fluoro-4-(trifluoromethyl)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-[2-ethoxy-4-(trifluoromethyl)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-[2-methoxy-4-(trifluoromethyl)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

3-[(4-methylpyrimidin-2-yl)methyl]-6-[2-methyl-4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 6-[2-fluoro-4-(trifluoromethoxy)phenyl]-3-[(4-methylpyrimidin-2-yl)methyl]-4H-1,3-benzoxazin-2-one;
 6-[2-methoxy-4-(trifluoromethoxy)phenyl]-3-[(4-methylpyrimidin-2-yl)methyl]-4H-1,3-benzoxazin-2-one;
 3-[(4-methylpyrimidin-2-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-4H-1,3-benzoxazin-2-one;
 3-[(4-methylpyrimidin-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 6-[2-propoxy-4-(trifluoromethoxy)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
 6-[2-propoxy-4-(trifluoromethyl)phenyl]-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
 and
 6-(2,2-difluoro-1,3-benzodioxol-5-yl)-3-(pyrimidin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;
 or a pharmaceutically acceptable salt thereof.

23. The compound according to claim 1 wherein:

R¹ is thiazolyl optionally substituted with C₁-C₆ alkyl;

R² and R^{2'} are both H;

R³ is H;

R⁴ is H;

R⁵ is a phenyl group optionally substituted with one or two groups independently selected from CH₃, -OCF₃, halogen, or -OCH₃;

R⁶ and R⁷ are both H; and

n is 1; or a pharmaceutically acceptable salt thereof.

24. The compound according to claim 22 selected from the group consisting of:

6-(4-chloro-3-fluorophenyl)-3-[(4-methyl-1,3-thiazol-2-yl)methyl]-4H-1,3-benzoxazin-2-one;

6-[2-methoxy-4-(trifluoromethoxy)phenyl]-3-[(4-methyl-1,3-thiazol-2-yl)methyl]-4H-1,3-benzoxazin-2-one;

6-[2-chloro-4-(trifluoromethoxy)phenyl]-3-[(4-methyl-1,3-thiazol-2-yl)methyl]-4H-1,3-benzoxazin-2-one;

6-(3,4-dichlorophenyl)-3-[(4-methyl-1,3-thiazol-2-yl)methyl]-4H-1,3-benzoxazin-2-one;

6-[2-fluoro-4-(trifluoromethoxy)phenyl]-3-[(4-methyl-1,3-thiazol-2-yl)methyl]-4H-1,3-benzoxazin-2-one;

3-[(4-methyl-1,3-thiazol-2-yl)methyl]-6-[3-methyl-4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;
 6-[3-fluoro-4-(trifluoromethoxy)phenyl]-3-[(4-methyl-1,3-thiazol-2-yl)methyl]-4H-1,3-benzoxazin-2-one; and
 3-[(4-methyl-1,3-thiazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one; or a pharmaceutically acceptable salt thereof.

25. The compound according to claim 1 wherein:

R¹ is pyridinyl optionally substituted with C₁-C₆ alkyl;

R² and R^{2'} are both H;

R³ is H;

R⁴ is H;

R⁵ is a phenyl group optionally substituted with one or two groups independently selected from CH₃, -OCF₃, halogen, or -OCH₃;

R⁶ and R⁷ are both H; and

n is 1; or a pharmaceutically acceptable salt thereof.

26. The compound according to claim 24 selected from the group consisting of:

6-[2-fluoro-4-(trifluoromethoxy)phenyl]-3-[(6-methylpyridin-2-yl)methyl]-4H-1,3-benzoxazin-2-one;

6-[2-methoxy-4-(trifluoromethoxy)phenyl]-3-[(6-methylpyridin-2-yl)methyl]-4H-1,3-benzoxazin-2-one;

6-[2-fluoro-4-(trifluoromethyl)phenyl]-3-[(6-methylpyridin-2-yl)methyl]-4H-1,3-benzoxazin-2-one;

6-[2-methoxy-4-(trifluoromethyl)phenyl]-3-[(6-methylpyridin-2-yl)methyl]-4H-1,3-benzoxazin-2-one;

3-(pyridin-2-ylmethyl)-6-[4-(trifluoromethyl)phenyl]-4H-1,3-benzoxazin-2-one;

6-[3-methyl-4-(trifluoromethoxy)phenyl]-3-(pyridin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-[2-methyl-4-(trifluoromethoxy)phenyl]-3-(pyridin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-[2-methoxy-4-(trifluoromethoxy)phenyl]-3-(pyridin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

6-[2-fluoro-4-(trifluoromethoxy)phenyl]-3-(pyridin-2-ylmethyl)-4H-1,3-benzoxazin-2-one;

3-(pyridin-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;

6-[2-methoxy-4-(trifluoromethoxy)phenyl]-3-(1-pyridin-2-ylcyclopropyl)-4H-1,3-benzoxazin-2-one;

6-[3-methyl-4-(trifluoromethoxy)phenyl]-3-(1-pyridin-2-ylcyclopropyl)-4H-1,3-benzoxazin-2-one;

6-[2-fluoro-4-(trifluoromethoxy)phenyl]-3-(1-pyridin-2-ylcyclopropyl)-4H-1,3-benzoxazin-2-one;

3-(1-pyridin-2-ylcyclopropyl)-6-[4-(trifluoromethyl)phenyl]-4H-1,3-benzoxazin-2-one;


3-(1-pyridin-2-ylcyclopropyl)-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;

3-(pyridin-4-ylmethyl)-6-[4-(trifluoromethyl)phenyl]-4H-1,3-benzoxazin-2-one; and

3-(pyridin-4-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-4H-1,3-benzoxazin-2-one;


or a pharmaceutically acceptable salt thereof.

27. A compound represented by the structure:




or a pharmaceutically acceptable salt thereof.

28. A compound represented by the structure:




or a pharmaceutically acceptable salt thereof.

29. A compound represented by the structure:



or a pharmaceutically acceptable salt thereof.

30. A compound represented by the structure:



or a pharmaceutically acceptable salt thereof.

31. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1 to 30 and a pharmaceutically acceptable excipient.

32. Use of a compound according to any one of claims 1 to 30 in the manufacture of a medicament for treating one or more diseases alleviable by treatment with an agent capable of reducing late sodium current, wherein the diseases are selected from diabetes, diabetic retinopathy, kidney disease, atrial arrhythmias, ventricular arrhythmias, heart failure, congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure, Prinzmetal's (variant) angina, stable angina, unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, LQT syndrome, hypertrophic cardiomyopathy, pulmonary hypertension and intermittent claudication.

33. The use according to claim 32 wherein the disease state is diabetes or diabetic peripheral neuropathy.

34. The use according to claim 32 wherein the disease state results in one or more of neuropathic pain, epilepsy, migraine, seizures or paralysis.

35. The use according to claim 32 wherein the disease state is Long QT syndrome.

36. The use of claim 35 wherein the Long QT syndrome is LQT1, LQT2, or LQT3.
37. The use according to claim 32 wherein the disease state is hypertrophic cardiomyopathy.
38. The use according to claim 32 wherein the disease state is ventricular tachycardia or ventricular fibrillation.
39. The use according to claim 32 wherein the disease state is atrial fibrillation.